MedTrace Logo

EpiCheck and Short-term Intensive Chemoresection in NMIBC

NCT04162704 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2021-08-11

No results posted yet for this study

Summary

The aim of this explorative study is to evaluate whether EpiCheck can be used as a predictor of tumour response to short-term, intensive chemoresection with Mitomycin.

Conditions

Interventions

DEVICE

EpiCheck

If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.

Sponsors & Collaborators

  • Aarhus University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-28
Primary Completion
2022-10-31
Completion
2022-10-31
FDA Device
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162704 on ClinicalTrials.gov